A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammatory mimics like MOGAD and NMOSD, even in seronegative cases.